Enhanced Susceptibility of HLA-mediated Ticlopidine-induced Idiosyncratic Hepatotoxicity by CYP2B6 Polymorphism in Japanese

被引:31
作者
Ariyoshi, Noritaka [1 ,4 ]
Iga, Yukako [2 ]
Hirata, Koji [3 ]
Sato, Yasunori [4 ,5 ]
Miura, Go
Ishii, Itsuko [2 ]
Nagamori, Seiji [6 ]
Kitada, Mitsukazu
机构
[1] Chiba Univ, Sch Med, Univ Hosp, Div Pharm,Chuo Ku, Chiba 2608677, Japan
[2] Chiba Univ, Grad Sch Med & Pharmaceut Sci, Chiba 2608677, Japan
[3] Daiichi, Prod Lifecycle Management Dept, Tokyo, Japan
[4] Chiba Univ Hosp, Clin Res Ctr, Chiba, Japan
[5] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA
[6] Kyorin Univ, Sch Med, Dept Pharmacol & Toxicol, Tokyo, Japan
关键词
ticlopidine-induced hepatotoxicity; HLA; metabolic activation; CYP2B6; interethnic difference; haplotype; HUMAN LIVER-MICROSOMES; INDUCED CHOLESTATIC HEPATITIS; TIENILIC ACID; MEPHENYTOIN HYDROXYLATION; ALLELE FREQUENCIES; IN-VITRO; METABOLITES; CLOPIDOGREL; CYTOCHROME-P-450; VARIABILITY;
D O I
10.2133/dmpk.25.298
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Hepatotoxicity is the most frequent adverse drug reaction (ADR) in Japanese treated with ticlopidine (TP). We investigated the relationship between CYP2B6 haplotype and incidence of TP-induced hepatotoxicity in 114 Japanese patients. Although 4 haplotypes (*1A, *1H, *1J and *6B) accounted for more than 80% of the inferred haplotypes in both control (n = 81) and case (n = 22) subjects, the prevalence was apparently different: control, *1A > *6B> *1H> *1J and case, *1J> *1H> *1A> *6B. The reporter gene assay for the two SNPs, which comprise the *1H or *1J haplotype, suggested that the *1H and *1J haplotypes may be associated with the increased expression of CYP2B6, probably due to g. -2320TAC. Combination analysis of CYP2B6 and human leukocyte antigen (HLA) haplotypes revealed that individuals possessing CYP2B6*1H or *1J with HLA-A*3303 have the highest susceptibility to TP-induced hepatotoxicity (odds ratio, 38.82; 95%CI, 8.08-196.0, P < 0.001). Although this is a preliminary case-control study with some limitations, it is the first example that HLA-induced idiosyncratic ADR may be modified by individual variation in CYP activities.
引用
收藏
页码:298 / 306
页数:9
相关论文
共 37 条
  • [31] Muchova Kraslova I, 2006, EUR J INFLAMM, V4, P55, DOI [10.1177/1721727X0600400107, DOI 10.1177/1721727X0600400107]
  • [32] Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients
    Nakajima, Miki
    Komagata, Sayaka
    Fujiki, Yuto
    Kanada, Yoshihiro
    Ebi, Hiromichi
    Itoh, Kuniaki
    Mukai, Hirofumi
    Yokoi, Tsuyoshi
    Minami, Hironobu
    [J]. PHARMACOGENETICS AND GENOMICS, 2007, 17 (06) : 431 - 445
  • [33] Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials
    O'Donoghue, Michelle L.
    Braunwald, Eugene
    Antman, Elliott M.
    Murphy, Sabina A.
    Bates, Eric R.
    Rozenman, Yoseph
    Michelson, Alan D.
    Hautvast, Raymond W.
    Lee, Peter N. Ver
    Close, Sandra L.
    Shen, Lei
    Mega, Jessica L.
    Sabatine, Marc S.
    Wiviott, Stephen D.
    [J]. LANCET, 2009, 374 (9694) : 989 - 997
  • [34] Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine
    Richter, T
    Mürdter, TE
    Heinkele, G
    Pleiss, J
    Tatzel, S
    Schwab, M
    Eichelbaum, M
    Zanger, UM
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 308 (01) : 189 - 197
  • [35] Ticlopidine-induced cholestatic hepatitis
    Skurnik, YD
    Tchemiak, A
    Edlan, K
    Sthoeger, Z
    [J]. ANNALS OF PHARMACOTHERAPY, 2003, 37 (03) : 371 - 375
  • [36] Lessons from ticlopidine-induced liver injury
    Takikawa, H
    [J]. HEPATOLOGY RESEARCH, 2005, 33 (03) : 193 - 194
  • [37] A natural CYP2B6 TATA box polymorphism (-82T→C) leading to enhanced transcription and relocation of the transcriptional start site
    Zukunft, J
    Lang, T
    Richter, T
    Hirsch-Ernst, KI
    Nussler, AK
    Klein, K
    Schwab, M
    Eichelbaum, M
    Zanger, UM
    [J]. MOLECULAR PHARMACOLOGY, 2005, 67 (05) : 1772 - 1782